ライフサイエンスコーパス: initial therapy

1 ancer recurring 6 months after completion of initial therapy.

2 rognostic markers and time from diagnosis to initial therapy.

3 eceived an endothelin receptor antagonist as initial therapy.

4 ave achieved disease control following their initial therapy.

5 eported, we analyzed the outcome of deferred initial therapy.

6 se can be made for adding rituximab to RI as initial therapy.

7 essive lymphoma is relapse or nonresponse to initial therapy.

8 ts with stable coronary disease when used as initial therapy.

9 and extended regimens might not be needed in initial therapy.

10 d patients with CML who received imatinib as initial therapy.

11 sporine or tacrolimus remain the standard as initial therapy.

12 or small lymphocytic lymphoma relapse after initial therapy.

13 ate time period is to measure the effects of initial therapy.

14 No recurrences were noted 12 months after initial therapy.

15 CP, both at baseline and 1 to 2 weeks after initial therapy.

16 and remain tumor free up to 10 months after initial therapy.

17 n the results and the time from diagnosis to initial therapy.

18 nting features, not all of whom responded to initial therapy.

19 mlodipine) or a beta-blocker (metoprolol) as initial therapy.

20 s MP; or intravenous MP alone (1 g/m(2)), as initial therapy.

21 r failure, active bleeding at endoscopy, and initial therapy.

22 day 1, but only 5% (2/40) had inappropriate initial therapy.

23 ndications, beta-blockers are recommended as initial therapy.

24 atients (8%) received transplants as part of initial therapy.

25 m diagnosis in 79% of those who responded to initial therapy.

26 prognosis HD treated with varying degrees of initial therapy.

27 levels of these polypeptides and response to initial therapy.

28 andomized patients received helium-oxygen as initial therapy.

29 ts with high-risk ALL and a slow response to initial therapy.

30 ildhood cancer decreases with more effective initial therapy.

31 efects with probing depths (PD) > 5 mm after initial therapy.

32 will either not respond to or relapse after initial therapy.

33 or thiazide-type diuretic is recommended as initial therapy.

34 performed approximately 2 months later after initial therapy.

35 omized trials comparing these two options as initial therapy.

36 be administered every 3 to 4 weeks IV during initial therapy.

37 d it is one of the most common components of initial therapy.

38 s because the major benefit results from the initial therapy.

39 atients will not respond to or relapse after initial therapy.

40 s with CML who were treated with imatinib as initial therapy.

41 spontaneous mutations largely independent of initial therapy.

42 ubsequent treatment can elucidate effects of initial therapies.

43 To evaluate idelalisib as initial therapy, 64 treatment-naive older patients with

44 ge III or IV follicular lymphoma received as initial therapy a single course of treatment with 131I-t

45 ents received a tyrosine kinase inhibitor as initial therapy, a proportion that increased to 94% for

46 le enzyme levels did not normalize with this initial therapy, additional medications were added in ra

47 d with study site (P = .03), nonadherence to initial therapy (adjusted odds ratio [AOR], 2.94; 95% CI

48 ariate analysis, advanced-stage, nonsurgical initial therapy, age 50 years or greater at diagnosis, a

49 s, multiple causes of symptoms, jaundice, an initial therapy algorithm, secondary therapy, and defini

50 Inadequate initial therapy also was an important risk factor for re

51 The median time from diagnosis to initial therapy among patients who did not have ZAP-70 w

52 knowledged before consideration of alternate initial therapies and when comparing results from curren

53 mmarizes the current recommendations for the initial therapy and describes the second and third-line

54 ng individual patients, both for response to initial therapy and during maintenance, a modified Sulcu

55 or this mutation may be useful for selecting initial therapy and for follow-up monitoring.

56 This indicates a need for more effective initial therapy and further studies of consolidation the

57 osed with ulcerative colitis to standardised initial therapy and identify predictors of treatment res

58 herapy for vasculitis both as a component of initial therapy and in the management of refractory dise

59 ho achieve a complete or partial response to initial therapy and may do so in similarly responding pa

60 A focus on the initial therapy and prophylaxis against chronic graft-ve

61 inical attachment loss > or = 5 mm following initial therapy and radiographic evidence of bone loss.

62 lysis (compared with peritoneal dialysis) as initial therapy and starting dialysis in more recent yea

63 ears of age or older, had a slow response to initial therapy, and entered remission at the end of ind

64 Data are emerging regarding their utility as initial therapy, and furthermore, they are been investig

65 , bleomycin, vinblastine, and dacarbazine as initial therapy, and granulocyte colony-stimulating fact

66 eventing disease relapse after diagnosis and initial therapy, and shifting the balance of the host-tu

67 ta regarding demographics, stage, histology, initial therapy, and survival were obtained on all patie

68 lenocytes were recovered >140 days after the initial therapy, and the L-selectinlow memory cell subse

69 and recent developments in the prophylaxis, initial therapy, and therapy for refractory disease are

70 t on the extent of the thrombus, response to initial therapy, and whether thrombophilic factors persi

71 ted with study site (P < .001), adherence to initial therapy (AOR, 0.26; 95% CI, 0.15-0.42; P < .001)

72 es were taken at baseline, 2 weeks after the initial therapy appointment, and 8 weeks after the compl

73 nd proteasome inhibitors-response rates with initial therapy are now between 70% and 100%.

74 creased after 21 days of therapy remained on initial therapy (arm B).

75 f therapy were randomly assigned to continue initial therapy (arm C1) or change to an alternative che

76 This review discusses remodeling, initial therapy based on neurohormonal modulation, and t

77 by dysregulated cyclin D1, responds well to initial therapy but is destined to relapse.

78 cell lymphoma (MCL) usually responds well to initial therapy but is prone to relapses with chemoresis

79 e, 28 to 80 years), were recruited requiring initial therapy by Groupe d'Etude des Lymphomes Follicul

80 ve a median time from diagnosis to requiring initial therapy by standard criteria of approximately 3

81 on of treatment resistance to ensure optimal initial therapy choice and regimen succession.

82 Decision-making regarding key questions of initial therapy choice, role of allografting, and change

83 e factors: number of metastases, response to initial therapy, CNS metastases, intrathoracic nodal sta

84 motif-1 had a median time from diagnosis to initial therapy comparable with that of cases without a

85 apies in those who chose sucralfate (61%) as initial therapy compared with overall respondents (26.9%

86 Patients received initial therapy consisting of oral hygiene instructions,

87 Current standard initial therapy consists of amphotericin B (AmB) plus fl

88 h DLBCL and 39% of patients with FL received initial therapy containing rituximab.

89 following were associated with inappropriate initial therapy: direct admission to hospital (not via e

90 ta suggest that in AML, (1) the selection of initial therapy dynamically templates the landscape of a

91 -label study, we compared three regimens for initial therapy: efavirenz plus two NRTIs (efavirenz gro

92 and sustained detumescence and should be the initial therapy employed for patients with SCA and prolo

93 he high expectation of cure (above 80%) with initial therapy, even for advanced disease, is tempered

94 agents or that they should be recommended as initial therapy, except in special situations.

95 or patients with del(17)(p13.1), no standard initial therapy exists, although several options support

96 After initial therapy failed, treatment with vancomycin and ri

97 We report the patterns of initial therapy focusing on the investigation of differe

98 icoids versus placebo and glucocorticoids as initial therapy for 243 patients who developed acute GVH

99 The standard initial therapy for acute graft-versus-host disease (GVH

100 The addition of MMF to corticosteroids as initial therapy for acute GVHD does not improve GVHD-fre

101 for 14 days, followed by an 8-week taper, as initial therapy for acute GVHD from 1990-2007 at the Uni

102 We conclude that etanercept plus steroids as initial therapy for acute GVHD results in a substantial

103 ids was superior to corticosteroids alone as initial therapy for acute GVHD.

104 d be incorporated as a means of intensifying initial therapy for advanced-stage, nonmetastatic HB.

105 to identify the most promising agent(s) for initial therapy for aGVHD.

106 The strategy using IFN with ribavirin as the initial therapy for all patients was associated with a c

107 n chemotherapy and an HER2-targeted agent as initial therapy for all patients with HER2-positive adva

108 f four patients who received lenalidomide as initial therapy for AML relapse after allogeneic transpl

109 Death within 1 year after initial therapy for AML.

110 Initial therapy for AML.

111 tion of ATRA and ATO (with or without GO) as initial therapy for APL was effective and safe and can s

112 high-dose bolus IL-2 should be considered as initial therapy for appropriately selected patients with

113 Anticoagulation is the preferred initial therapy for cancer patients with central venous

114 e plus prednisone versus prednisone alone as initial therapy for chronic GHVD among patients whose pl

115 Adefovir appears to be safe and effective as initial therapy for chronic hepatitis B virus infection

116 of t-MN occurred at a median of 5 years from initial therapy for chronic lymphocytic leukemia, 9 afte

117 closporine or tacrolimus was administered as initial therapy for clinical extensive chronic graft-ver

118 IFN-alpha is now often used as initial therapy for CML, before donor availability is kn

119 PCD should be considered as the initial therapy for culture-positive patients, with surg

120 Although initial therapy for cytomegalovirus (CMV) is usually suc

121 one patient who refused cyclophosphamide as initial therapy for diffuse proliferative nephritis but

122 n (LR), and radiofrequency ablation (RFA) as initial therapy for early hepatocellular carcinoma (HCC)

123 The best initial therapy for elderly patients with chronic lympho

124 investigated the activity of lenalidomide as initial therapy for elderly patients with CLL.

125 omized to antitachycardia pacing or shock as initial therapy for FVT.

126 r regimen of atazanavir (ATV)/RTV+FTC/TDF as initial therapy for HIV-1 infection.

127 d four once-daily antiretroviral regimens as initial therapy for HIV-1 infection: abacavir-lamivudine

128 Limited data compare once-daily options for initial therapy for HIV-1.

129 of lenalidomide plus rituximab was active as initial therapy for mantle-cell lymphoma.

130 ids and immunosuppression may be a preferred initial therapy for many noninfectious, intermediate, po

131 cessary dialysis and should be emphasized as initial therapy for many patients with end-stage renal d

132 All patients received tamoxifen as initial therapy for metastatic disease.

133 lenalidomide plus dexamethasone (Rev/Dex) as initial therapy for myeloma.

134 y combining thalidomide and dexamethasone as initial therapy for myeloma.

135 s of receiving bevacizumab vs ranibizumab as initial therapy for neovascular AMD among US Medicare be

136 thalidomide plus dexamethasone (thal/dex) as initial therapy for newly diagnosed myeloma.

137 idomide has evidence of clinical activity as initial therapy for older AML patients, and further stud

138 for selective laser trabeculoplasty (SLT) as initial therapy for open-angle glaucoma and ocular hyper

139 inuous positive airway pressure treatment as initial therapy for patients diagnosed with OSA.

140 e) regimens without rituximab maintenance as initial therapy for patients with advanced-stage follicu

141 that CIFN at a dose of 9 microg is effective initial therapy for patients with chronic hepatitis C, a

142 in most clinical scenarios, a cost-effective initial therapy for patients with chronic-phase CML who

143 se results, we are currently studying PCR as initial therapy for patients with CLL.

144 we investigate the efficacy of dasatinib as initial therapy for patients with CML in early chronic p

145 iptase inhibitors (NRTIs) is recommended for initial therapy for patients with human immunodeficiency

146 this study, the use of MTX and prednisone as initial therapy for patients with WG-related glomerulone

147 ccording to consensus-based recommendations, initial therapy for PMR is prednisone, 12.5 to 25 mg/day

148 Xerosis treatment should be included in the initial therapy for pruritus in all elderly patients.

149 duction in immunosuppression is an effective initial therapy for PTLD.

150 explore reduction in immunosuppression as an initial therapy for PTLD.

151 ntially curative and should be considered as initial therapy for such patients.

152 ies supporting the use of fludarabine as the initial therapy for symptomatic disease.

153 The initial therapy for symptomatic patients with obstructio

154 Plasma exchange is the most effective initial therapy for TTP to date.

155 ow molecular weight heparin is the preferred initial therapy for VTE.

156 Initial therapy for warm antibody autoimmune hemolytic a

157 2) a subclone of the founding clone survived initial therapy, gained additional mutations and expande

158 similar proportions in each group continuing initial therapy had HIV RNA levels of less than 10000 co

159 cs of patients with lupus nephritis ESRD and initial therapies have changed in recent years.

160 eaving the operating room in cases where the initial therapies have had little impact.

161 s of observing asymptomatic patients without initial therapy, ie, "watch and wait." Since the initial

162 opportunity to compare the effectiveness of initial therapies in MCL.

163 Antiarrhythmic medications were used for initial therapy in 154 patients with control of FAT in 7

164 ry NGAL may guide differential diagnosis and initial therapy in allograft recipients with AKI.

165 The use of second-generation TKIs as initial therapy in CML induces high rates of CCyR at ear

166 Purpose Sunitinib is a standard initial therapy in metastatic renal cell carcinoma (mRCC

167 y of the hypomethylating agent decitabine as initial therapy in older patients with AML.

168 Guidelines for selection of ART as initial therapy in patients with HIV-1 infection do not

169 boosted protease inhibitor is recommended as initial therapy in patients with human immunodeficiency

170 as not achieved with infusional CDE given as initial therapy in patients with poor-risk intermediate-

171 s make it worthy of further study as part of initial therapy in randomized protocols for high-risk di

172 rred (usually along with a diuretic drug) as initial therapy in several subsets of hypertensive patie

173 Doxorubicin can be omitted as part of initial therapy in the majority of these patients, poten

174 oglobulin (IVIG) and aspirin is the standard initial therapy in the treatment of Kawasaki disease.

175 The clinical success rates of the initial therapy in the two groups were 61 and 84%, respe

176 and deserves further clinical evaluation as initial therapy in these infections.

177 to the other antiretroviral regimens used as initial therapy in this study.

178 CLL cells, the median time from diagnosis to initial therapy in those who had an unmutated IgV(H) gen

179 a also suggest that VRC should be avoided as initial therapy in unstable patients with invasive candi

180 lls, preferably within the first 4 cycles of initial therapy, in patients treated with novel agents a

181 Initial therapy included combination chemotherapy and su

182 Reasons for no initial therapy included: physician choice (n = 20), lar

183 rally similar vertical bony defects received initial therapy including scaling and root planing follo

184 In this multicenter trial we compared initial therapy involving four-drug regimens containing

185 Initial therapy is deferred in a small subset of patient

186 For prolactinomas, initial therapy is generally dopamine agonists.

187 For all other pituitary adenomas, initial therapy is generally transsphenoidal surgery wit

188 n independent predictor of mortality; and 2) initial therapy is predictive of mortality among African

189 myeloma who received this class of drugs for initial therapy is unknown.

190 CL-1/BCL-XL and (2) appropriate selection of initial therapy may delay or altogether forestall the ac

191 as improved over time and that the choice of initial therapy may matter.

192 rty-one patients treated with pentostatin as initial therapy (n = 154) or who crossed over after fail

193 The concept of periodontal reevaluation of initial therapy needs to be revisited.

194 ission during the first 6-month period after initial therapy (nonrelapsers; 40% of the entire series)

195 initial bulk, histology, grade, response to initial therapy, number of prior regimens, time from dia

196 linical presentation, diagnostic workup, and initial therapy of 2 of these patients.

197 teroids and daclizumab should not be used as initial therapy of acute GVHD.

198 t of comorbidities on 1-year mortality after initial therapy of acute myeloid leukemia (AML) and (2)

199 mia (CML) and are now widely accepted as the initial therapy of choice in this disease, supplanting i

200 recently approved with chlorambucil for the initial therapy of chronic lymphocytic leukemia (CLL).

201 e randomized intergroup phase 3 E2997 trial, initial therapy of chronic lymphocytic leukemia with flu

202 patients showed that it was highly active as initial therapy of chronic lymphocytic leukemia.

203 r both of these 'second-generation' TKIs for initial therapy of CML.

204 have also demonstrated effectiveness in the initial therapy of earlier stages of cancer, a setting i

205 ted (90)Y-ibritumomab tiuxetan ((90)Y-IT) as initial therapy of follicular lymphoma (FL).

206 Initial therapy of hypertension with beta-blockers is no

207 chronic lymphocytic leukemia treated with an initial therapy of lenalidomide.

208 Initial therapy of metastatic breast cancer with paclita

209 aim is to review current recommendations for initial therapy of patients with early chronic phasechro

210 For initial therapy of patients with liver disease, we use a

211 For initial therapy of patients with neurologic disease we u

212 d empirical ATP (n=313) or shock (n=321)-for initial therapy of spontaneous FVT.

213 ne the impact of HCA cSSTI and inappropriate initial therapy on outcomes.

214 (1) had a new diagnosis and were planned for initial therapy or (2) had developed acquired resistance

215 Disease progression may occur during initial therapy or after complete eradication in a small

216 st cancer includes an aromatase inhibitor as initial therapy or after treatment with tamoxifen.

217 an be effectively treated with a diuretic as initial therapy or as part of a combination regimen.

218 on alfa-2b alone or with ribavirin either as initial therapy or for interferon relapse.

219 r secondary open angle glaucomas, both as an initial therapy or in conjunction with hypotensive medic

220 ested with the aim of decreasing the cost of initial therapy or to improve compliance, but abbreviate

221 strogen tamoxifen will either not respond to initial therapy or will develop drug resistance.

222 ial examination; 4 weeks after completion of initial therapy (oral hygiene counseling, and scaling an

223 receiving iodine I(131) tositumomab as their initial therapy (P = .011 compared with previously treat

224 an altered local inflammatory response after initial therapy, perhaps symptomatic of colonization by

225 refore, knowledge of RER status could affect initial therapy, postoperative chemotherapy, and follow-

226 Achievement of VGPR or better with this initial therapy predicted longer PFS, regardless of the

227 atient received oral hygiene instruction and initial therapy prior to surgery.

228 arly after 9 months to the limited amount of initial therapy provided.

229 m outcomes were compared on the basis of the initial therapy received.

230 b- and imatinib-treated patients remained on initial therapy, respectively.

231 various stages of myeloma therapy, including initial therapy resulting in improvement of disease cont

232 Initial therapy should be amoxicillin in a high dosage (

233 Despite favorable responses to initial therapy, small-cell lung cancer (SCLC) relapse o

234 After initial therapy, smokers exhibited significantly less re

235 therapy (seizure density), poor response to initial therapy, some epilepsy syndromes.

236 acute myeloid leukemia (AML) who respond to initial therapy subsequently relapse.

237 lamic brain regions in glioma patients after initial therapy, suggesting treatment effects on the ser

238 argely weighted to maintenance as opposed to initial therapy, switching from more potent to less expe

239 data suggest the same for patients receiving initial therapies that did not contain cytarabine.

240 A secondary outcome was time to receipt of initial therapy that was evaluated using Cox shared frai

241 ervational period' (excluding extractions at initial therapy), the average tooth loss for AgP was 0.0

242 symptoms, and despite the early induction of initial therapy, the symptoms became worse.

243 om study entry until either reinstitution of initial therapy, therapy with a second agent, or death).

244 If patients had a good response to initial therapy, they proceeded to consolidation therapy

245 Use of imaging after initial therapy to assess for recurrence and to plan sal

246 amine agonists can be used as an alternative initial therapy to delay the onset of motor complication

247 ased oxygen carriers can adequately serve as initial therapy to maintain tissue oxygen delivery while

248 ); and also did a second randomisation after initial therapy to maintenance chemotherapy (fluorouraci

249 nd to determine the best time interval after initial therapy to perform a reevaluation based on class

250 have a relapse in symptoms after successful initial therapy, usually in the first few weeks after tr

251 patients with indolent lymphomas respond to initial therapy, virtually all experience relapse.

252 urvival of patients who received imatinib as initial therapy was 89% at 60 months.

253 ilure to achieve control of AD symptoms with initial therapy was associated with a higher risk of rel

254 Initial therapy was designated "appropriate" versus "ina

255 atment of chronic-phase CML with imatinib as initial therapy was found to induce durable responses in

256 Initial therapy was not predictive of survival among Afr

257 mporaneous patients with GVHD (n = 99) whose initial therapy was steroids alone.

258 , the objective response rates observed with initial therapy were 32% for arm 1, 24% for arm 2, and 1

259 Patients who sustained remission after initial therapy were distinguished only by a lower serum

260 were in their first relapse or refractory to initial therapy were randomly assigned to one of two sal

261 alis) and Tannerella forsythia who completed initial therapy were randomly assigned to receive SubGPA

262 00 for relapse of GCT more than 2 years from initial therapy were reviewed.

263 ), Q-wave infarction, in-hospital death, and initial therapy were studied.

264 P < 0.05) in clinical attachment level after initial therapy when compared to baseline readings.

265 ad reduction of immunosuppression as part of initial therapy, whereas 59 (74%) of 80 patients receive

266 All patients underwent initial therapy, which included scaling and root planing

267 and plaque index (PI) were measured prior to initial therapy, which involved oral hygiene instruction

268 ent recommendations for hypertension include initial therapy with a diuretic or beta-adrenergic block

269 ly for 7 days (estimated cost, $5.51) and 2) initial therapy with azithromycin, 1 g orally administer

270 arly clinical studies have demonstrated that initial therapy with combined BRAF and MEK inhibition is

271 Initial therapy with dose-adjusted intravenous unfractio

272 ical chlamydial infections were compared: 1) initial therapy with doxycycline, 100 mg orally twice da

273 nic lymphocytic leukemia (CLL) have received initial therapy with fludarabine as a single agent or fl

274 In patients with chronic hepatitis C, initial therapy with interferon and ribavirin was more e

275 tification systems among patients undergoing initial therapy with lenalidomide in the context of a ph

276 We studied the outcome after initial therapy with lenalidomide-dexamethasone among 10

277 rubicin, vincristine, and prednisone (CHOP), initial therapy with more dose-intense regimens resulted

278 In patients with early seropositive RA, initial therapy with MTX plus doxycycline was superior (

279 All patients received initial therapy with open-label enoxaparin or unfraction

280 re intensive schedules of the drugs used for initial therapy with or without haemopoietic stem cell t

281 with chronic hepatitis C fail to respond to initial therapy with pegylated interferon (PEG-IFN) and

282 r primary carcinoma of the peritoneum; prior initial therapy with platinum/paclitaxel; and failure to

283 rvational data, suggest that the benefits of initial therapy with rituximab in a heterogeneous group

284 cohorts with less than a partial response to initial therapy with single-agent CP-751,871.

285 ors, including those that had recurred after initial therapy with temozolomide.

286 We conducted a randomized trial of initial therapy with zidovudine and lamivudine plus eith

287 Several regimens are acceptable as initial therapy, with tenofovir/emtricitabine/efavirenz

288 ected that patients relapsing after inferior initial therapy would have a higher retrieval rate than

289 Corticosteroids remain the standard initial therapy, yet only 25% to 41% of patients complet